Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Inclusion Criteria: * Patients with sarcoma which is locally advanced, at high risk for relapsed or metastatic for whom treatment with AI is indicated * Must be between 18-65 years of age * Women of childbearing potential should use effective contraceptive measures * Adequate hematologic, renal, and hepatic functions * Karnofsky performance status above or equal to 80 Exclusion Criteria: * Pregnant or lactating women. * Patients with comorbid condition which renders patients at high risk of treatment complication * Patients with metastatic disease to CNS * Patients with significant cardiac abnormalities * History of seizure disorder in the past 5 years * Patient has received any packed red blood cell transfusion within 2 weeks before study entry * Prior surgery or radiation therapy within 2 weeks of study entry * History of prior chemotherapy for sarcomas * Iron deficiency * Hypersensitivity to E.coli derived products